MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD – Get Free Report) fell 2.6% on Tuesday . The company traded as low as $1.90 and last traded at $1.90. 40,763 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 134,123 shares. The stock had previously closed at $1.95.
MyMD Pharmaceuticals Stock Performance
The company has a 50-day moving average of $1.86 and a 200-day moving average of $2.38.
MyMD Pharmaceuticals Company Profile
MyMD Pharmaceuticals, Inc, a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression.
Featured Articles
- Five stocks we like better than MyMD Pharmaceuticals
- Which Wall Street Analysts are the Most Accurate?
- Study: How Much Are Retirees Earning from Side Hustles in 2024?
- The How and Why of Investing in Gold Stocks
- Brinker International Offers a Pullback Opportunity on EPS Miss
- What is a Secondary Public Offering? What Investors Need to Know
- Globant Is an Emerging AI Play That’s Expanding Its Footprint
Receive News & Ratings for MyMD Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyMD Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
